Search Results
Nov 20, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Nov 20, 2025, 09:55 ET Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments
San Francisco, San Francisco, CA, USAGene Therapy for the Progressive, Debilitating, Multisystem COPA Syndrome Mingshan Xue, PhD – Baylor College of Medicine, Houston, TX, USAGene Therapy for the Catastrophic CASK-Related Neurodevelopmental
More news about: Harrington Discovery Institute
Nov 20, 2025, 09:43 ET ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform
core leadership team includes: Dr. Lior Nissim, Head of the Biomedical Synthetic Biology Lab, who pioneered the first synthetic gene circuit for precise targeting of cancer cells; Prof. Chezy Barenholz, a long-time leader in liposome technology and nanomedicine,
More news about: ViVac Pharma Ltd.
Nov 20, 2025, 09:42 ET Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments
San Francisco, San Francisco, CA, USAGene Therapy for the Progressive, Debilitating, Multisystem COPA Syndrome Mingshan Xue, PhD – Baylor College of Medicine, Houston, TX, USAGene Therapy for the Catastrophic CASK-Related Neurodevelopmental
More news about: Harrington Discovery Institute
Nov 20, 2025, 09:00 ET ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
a neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the huntingtin (HTT) gene. Individuals with HD have more than 36 CAG repeats in the HTT gene, resulting in the production of mutant huntingtin protein, which leads to the synthesis of mutant huntingtin protein
More news about: ReviR Therapeutics
Nov 20, 2025, 08:04 ET BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence
BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced the opening of the Aby J. Mathew Center for Biopreservation Excellence. Located within the company's newly expanded
More news about: BioLife Solutions, Inc.
Nov 20, 2025, 08:00 ET ALS Network and ALS United Announce New Research Grantees
Claire Clelland, PhD, MD, University of California San Francisco for Rapid Screening of a Miniaturized Cas and gRNAs for AAV Delivery of C9orf72 Gene Therapy. Richard Daneman, PhD; John Ravits, MD, University of California San Diego
More news about: ALS Network
Nov 20, 2025, 07:00 ET SciNeuro Pharmaceuticals to Accelerate Novel LRRK2 Therapeutic (SNP614) Development with an Award from The Michael J. Fox Foundation
leaders, and provide preclinical and clinical resources to establish best practices for advancing LRRK2 targeted therapeutics. Mutations in the LRRK2 gene linked to Parkinson's disease were first discovered in 2004 and are now understood to be the most common cause of inherited PD. Built on MJFF's dedication
More news about: SciNeuro Pharmaceuticals
Nov 20, 2025, 05:03 ET LUNGevity Invests in Lung Cancer Workforce Expansion Through Four Strategic Research Awards
Dr. Ogidigo will investigate how obesity affects lung cancer development using a diet-induced obesity mouse model and studying many factors, including gene expression, metabolism, and epigenetic modifications. She will also study the use of metabolism-targeting drugs to slow tumor growth. By building our
More news about: LUNGevity Foundation
Nov 20, 2025, 00:01 ET Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
characterize immune phenotypes across different types of MET alterations, including exon 14 skipping, amplification, or no mutation (wildtype). Immune gene expression analysis further validated the AI-defined immune phenotypes and revealed key immune response pathways driving the inflamed phenotype, underscoring
More news about: Lunit
Nov 19, 2025, 17:31 ET KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
Therapeutics' Lonvo-z, previously known as NTLA-2002, is an investigational in vivo CRISPR-based gene editing therapy designed to prevent hereditary angioedema (HAE) attacks by inactivating the KLKB1 gene, which encodes prekallikrein, the precursor to kallikrein. The therapy has earned five key regulatory
More news about: DelveInsight Business Research, LLP
Nov 19, 2025, 10:10 ET Cell Culture Media Market Outlook: Strong 13.2% CAGR to Drive $12.8 Billion Revenue by 2033 - Grand View Research, Inc.
Development Tissue Engineering and Regenerative Medicine Cell and Gene Therapy Other Tissue Engineering and Regenerative Medicine Applications
More news about: Grand View Research, Inc.
Nov 19, 2025, 10:00 ET VMX 2026: Can't-Miss Sessions Led by the Brightest Minds in Veterinary Medicine
Acupuncture for the Aging Patient." Gene O'Neill, NAVC CEO, added: "Veterinarians today are leading extraordinary change in how care is delivered and defined. Through VMX 2026, NAVC is able
More news about: North American Veterinary Community (NAVC)
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
High-Speed Protein Production Across Six Expression Systems Tsingke Biotech combines advanced gene synthesis, automated expression, and purification technologies to deliver rapid protein production. The company supports six expression
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
High-Speed Protein Production Across Six Expression Systems Tsingke Biotech combines advanced gene synthesis, automated expression, and purification technologies to deliver rapid protein production. The company supports six expression
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 09:13 ET Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene to enable dystrophin production in people living with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44). DMD is characterized
More news about: Avidity Biosciences, Inc.
Nov 19, 2025, 09:02 ET Safeguard Global Maps Hotspots to Find Pharma Talent in Inaugural Industry Intelligence Report
Holland) Nineteen of the world's top 20 biopharma firms operate in Ireland, which has developed a strong reputation for cell and gene therapies. (Source: Innopharma education) "Pharma teams across the globe are seeking to understand where
More news about: Safeguard Global
Nov 19, 2025, 09:00 ET ToolGen Completes U.S. Patent Registration for Core CRISPR Cas9 RNP Technology; Files U.S. Lawsuit Related to CASGEVY®
About ToolGen ToolGen (KOSDAQ: 199800) is a biotechnology company focused on developing and commercializing gene-editing platform technologies and applications across human therapeutics, agriculture, and industrial biotechnology. CASGEVY®
More news about: ToolGen
Nov 19, 2025, 07:30 ET Autoimmunity BioSolutions Bolsters Leadership Team
Strategy. "I am very grateful that each of these highly experienced and capable individuals has chosen to join the ABS team," said CEO Gene Williams, MBA. "With this team, we are well positioned to build a company providing great benefit to patients, therapy that is personalized and immuno-corrective
More news about: Autoimmunity BioSolutions
Nov 19, 2025, 07:00 ET Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex
More news about: Genprex, Inc.
Nov 19, 2025, 06:45 ET Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
hallmark of the Gateway Labs approach. "Philadelphia has long led biotech innovation, from early vaccine development to pioneering gene therapy and CAR-T treatments and discovering new approaches to Alzheimer's disease. Today's local biotech scene builds on that legacy with founders
More news about: Eli Lilly and Company
Nov 19, 2025, 02:48 ET Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information
More news about: Piramal Pharma Solutions
Nov 19, 2025, 02:41 ET Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information
More news about: Piramal Pharma Solutions
Nov 19, 2025, 02:34 ET New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management
technology and AI are accelerating the growth of precision diagnostics in bladder cancer. The pharmaceutical advancements, with emerging immune and gene therapies, are transforming care. This requires a more precise diagnosis to better select patients, predict and monitor treatment response and thus
More news about: Photocure
Nov 18, 2025, 11:06 ET European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated